Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HIWOLFIA vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective agonist at central nervous system GABA-A receptors, enhancing inhibitory neurotransmission.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Sedation,Anxiety disorders,Insomnia
Hypertension
Not established; investigational agent.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 18 hours (range 14-22 hours). Clinically, this supports once-daily dosing in most patients; however, in renal impairment (Cr Cl <30 m L/min), half-life extends to 40 hours, requiring dose adjustment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite formed.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal excretion accounts for 70% of elimination, with 30% via biliary/fecal routes. Of the renal component, 90% is eliminated unchanged, 10% as metabolites.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
92% bound to albumin and alpha-1-acid glycoprotein (AAG). Binding is concentration-independent within therapeutic range.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Volume of distribution is 0.45 L/kg (range 0.35-0.55 L/kg), indicating moderate distribution into total body water. Higher Vd in obesity (0.65 L/kg) suggests sequestration in adipose tissue.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 65% (range 55-75%), with first-pass metabolism reducing bioavailability. No data for other non-parenteral routes.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No data available.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
No data available.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific recommendations.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Risk of respiratory depression when combined with other CNS depressants; avoid concurrent use of opioids, alcohol, or benzodiazepines.
None
May cause sedation, dizziness, and impaired motor coordination; avoid driving or operating machinery. Use with caution in hepatic impairment. Risk of abuse and dependence.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Severe respiratory insufficiency; myasthenia gravis; hypersensitivity to drug or its components.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
No documented food interactions for this fictitious drug.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Risk of major congenital malformations, including neural tube defects and cardiovascular anomalies, based on animal studies (FDA Pregnancy Category X). Second and third trimesters: Fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Contraindicated in pregnancy.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted into breast milk; M/P ratio unknown. Potential for severe adverse effects in nursing infants, including hypotension and respiratory depression. Contraindicated during breastfeeding.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Increased clearance and volume of distribution in pregnancy necessitate dose adjustments; may require higher doses to maintain therapeutic effect, but contraindicated due to teratogenicity. No dose recommendation in pregnancy.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
HIWOLFIA is a fictitious drug with no established clinical data. No clinical pearls can be provided.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
No validated patient counseling points exist for this fictitious drug.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HIWOLFIA vs ALDORIL D30, answered by our medical review team.
HIWOLFIA is a Antihypertensive that works by Selective agonist at central nervous system GABA-A receptors, enhancing inhibitory neurotransmission.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HIWOLFIA and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HIWOLFIA is: Not established; investigational agent.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HIWOLFIA and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HIWOLFIA is classified as Category C. First trimester: Risk of major congenital malformations, including neural tube defects and cardiovascular anomalies, based on animal studies (FDA Pregnancy Category X). Second and . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.